These anti-TNF therapeutics, and biosimilars of infliximab, etanercept and adalimumab that have been approved recently, are successfully used to treat autoimmune diseases, including RA, juvenile RA (JRA), IBD, psoriasis, and ankylosing spondylitis (AS) (Monaco et al., 2015). This evidence concerns the gene TNF and rheumatoid arthritis.